A short report on highlights of world-wide development of RIX4414: an European experience

Vaccine. 2006 May 1;24(18):3779. doi: 10.1016/j.vaccine.2005.07.028. Epub 2005 Aug 1.

Authors

T Vesikari¹, A Karvonen, L Puustinen, E D Szakal, S-Q Zeng, A Delem, B De Vos

Affiliation

¹ University of Tampere, Medical School/FM3, Vaccine Research Center, University of Tampere, 33014 Tampere, Finland. timo.vesikari@uta.fi

PMID: 16581159
DOI: 10.1016/j.vaccine.2005.07.028

No abstract available

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Administration, Oral
Antibodies, Viral / blood
Belgium
Clinical Trials, Phase I as Topic
Clinical Trials, Phase II as Topic
Double-Blind Method
Feces / virology
Finland
Gastroenteritis / epidemiology
Gastroenteritis / prevention & control*
Humans
Immunoglobulin A / blood
Infant
Randomized Controlled Trials as Topic
Rotavirus / immunology*
Rotavirus Infections / epidemiology
Rotavirus Infections / prevention & control*
Rotavirus Vaccines* / administration & dosage
Rotavirus Vaccines* / adverse effects
Rotavirus Vaccines* / immunology
Vaccines, Attenuated* / administration & dosage
Vaccines, Attenuated* / adverse effects
Vaccines, Attenuated* / immunology
Virus Shedding

Substances

Antibodies, Viral
Immunoglobulin A
RIX4414 vaccine
Rotavirus Vaccines
Vaccines, Attenuated